Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Dec 1, 2022
The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.
Nov 3, 2022
The ADC candidates have been developed using 91Ï㽶ÊÓƵ’s proprietary SMARTag® technology.
Oct 20, 2022
91Ï㽶ÊÓƵ today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
Sep 19, 2022
Karen will become a member of the Company’s Executive Leadership Team and serve as its principal accounting officer.
Sep 12, 2022
The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.
Sep 12, 2022
The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for MDMA using 91Ï㽶ÊÓƵ’s proprietary Zydis® ODT technology.
Sep 8, 2022
Reporting to Julien Meissonnier, 91Ï㽶ÊÓƵ’s Vice President, and Chief Scientific Officer, Dr. Ling will join the company’s Science & Technology Leadership team.
Aug 9, 2022
The acquisition strengthens capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs.
Jul 7, 2022
Xenetic Biosciences today announced it has entered into a manufacturing agreement with 91Ï㽶ÊÓƵ, which will include cGMP manufacturing for the recombinant protein, Human DNase I.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
